Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist comprehensive Cancer Center

Theranostics

Volumn 7, Issue 11, 2017, Pages 2914-2923

  Kytola, Ville ^a,b,c   Topaloglu, Umit ^a,b   Miller, Lance D ^a,b   Bitting, Rhonda L ^a,b   Goodman, Michael M ^a,b   D'Agostino, Ralph B ^a,b   Desnoyers, Rodwige J ^a,b   Albright, Carol ^a,b   Yacoub, George ^a,b   Qasem, Shadi A ^a,b   DeYoung, Barry ^a,b   Thorsson, Vesteinn ^d   Shmulevich, Ilya ^d   Yang, Meng ^a,b,e   Shcherban, Anastasia ^a,b,c   Pagni, Matthew ^a,b   Liu, Liang ^a   Nykter, Matti ^c   Chen, Kexin ^e   Hawkins, Gregory A ^a,b   Grant, Stefan C ^a,b   Petty, W Jeffrey ^a,b   Alistar, Angela Tatiana ^a,b   Levine, Edward A ^a,b   Staren, Edgar D ^a,b   Langefeld, Carl D ^b   Miller, Vincent ^f   Singal, Gaurav ^f   Petro, Robin M ^a,b   Robinson, Mac ^a   Blackstock, William ^a,b   Powell, Bayard L ^a,b   Wagner, Lynne I ^a,b   Foley, Kristie L ^a,b   Abraham, Edward ^b   Pasche, Boris ^a,b   Zhang, Wei ^a,b   more..

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^e TIANJIN MEDICAL UNIVERSITY   (China)

^f FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN;

AFRICAN AMERICAN; ARTICLE; ATM GENE; BLADDER CANCER; BRCA2 GENE; CAUCASIAN; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HIGH FREQUENCY MUTATION; HUMAN; HUMAN TISSUE; KMT2C GENE; KMT2D GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MLL2 GENE; MLL3 GENE; MUTATION RATE; MUTATIONAL LOAD; SMOKING; SMOKING RELATED CANCER; TP53 GENE; BLADDER TUMOR; COLORECTAL TUMOR; DNA SEQUENCE; GENETICS; LUNG TUMOR; MOLECULAR PATHOLOGY; MUTATION; PATHOLOGY;

AFRICAN AMERICANS; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LUNG NEOPLASMS; MUTATION; PATHOLOGY, MOLECULAR; SEQUENCE ANALYSIS, DNA; TOBACCO SMOKING; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 85025444732     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.20355     Document Type: Article

References (41)

1. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 2004; 4: 519-27.
2. Carr TH, McEwen R, Dougherty B, et al. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer. 2016; 16: 319-29.
3. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372: 793-5.
4. Morris LG, Chandramohan R, West L, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA Oncol. 2016; 3: 244-55.
5. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998-2006.
6. Sonnenblick A, Ponde N, Piccart M. Metastatic breast cancer: The Odyssey of personalization. Mol Oncol. 2016; 10: 1147-59.
7. Tran NH, Cavalcante LL, Lubner SJ, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015; 7: 252-62.
8. Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA. 2014; 311: 1975-6.
9. Jurgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res. 2014; 20: 4425-35.
10. Ornes S. Core Concept: Basket trial approach capitalizes on the molecular mechanisms of tumors. Proc Natl Acad Sci U S A. 2016; 113: 7007-8.
11. [Internet]. ECOG-ACRIN Cancer Research Group. NCI-MATCH / EAY131 Interim Analysis.; 2016. http://ecog-acrin.org/nci-match-eay131/interim-analysis.
12. Harris MH, DuBois SG, Glade Bender JL, et al. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016; 2: 608-15.
13. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002; 21: 7435-51.
14. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009; 69: 3681-8.
15. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016; 66: 290-308.
16. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-31.
17. La Vecchia C, Franceschi S, Bosetti C, et al. Time since stopping smoking and the risk of oral and pharyngeal cancers. J Natl Cancer Inst. 1999; 91: 726-8.
18. [Internet]. U.S. Department of Health and Human Services. US Surgeon General's Report, 2010: U.S. Department of Health and Human Services. A Report of the Surgeon General. How Tobacco Smoke Causes Disease: What It Means to You. . Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010 [accessed 2015 Oct 19]. https://www.cdc.gov/tobacco/data_statistics/sgr/2010/consumer_booklet /.
19. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988; 75: 800-2.
20. R Core Team. A language and environment for statistical computing. 3.3.0 ed. Vienna, Austria: R Foundation for Statistical Computing. 2016. https://www.R-project.org.
21. Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10: e1003665.
22. Ceccarelli M, Barthel FP, Malta TM, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164: 550-63.
23. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013; 4: 2185.
24. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-7.
25. Chen K, Yang D, Li X, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015; 112: 1107-12.
26. Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016; 354: 618-22.
27. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992; 358: 15-6.
28. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010; 2: a001016.
29. Campbell JD, Lathan C, Sholl L, et al. Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncol. 2017: doi: 10.1001/jamaoncol.2016.6108.
30. MacConaill LE, Lindeman NI, Rollins BJ. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality. JAMA Oncol. 2015; 1: 879-80.
31. Meric-Bernstam F, Johnson A, Holla V, et al. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015; 107: doi: 10.1093/jnci/djv098.
32. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014; 74: 7181-4.
33. Mody RJ, Wu YM, Lonigro RJ, et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA. 2015; 314: 913-25.
34. Jameson JL, Longo DL. Precision medicine--personalized, problematic, and promising. N Engl J Med. 2015; 372: 2229-34.
35. Miller FA, Hayeems RZ, Bytautas JP, et al. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet. 2014; 22: 391-5.
36. Sohal DP, Rini BI, Khorana AA, et al. Prospective Clinical Study of Precision Oncology in Solid Tumors. J Natl Cancer Inst. 2016; 108: doi: 10.1093/jnci/djv332.
37. Darrow JJ, Sarpatwari A, Avorn J, et al. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015; 372: 279-86.
38. Carter H, Chen S, Isik L, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009; 69: 6660-7.
39. Linnekamp JF, Wang X, Medema JP, et al. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 2015; 75: 245-9.
40. Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL, et al. Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol. 2013; 31: 1842-8.
41. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015; 526: 361-70.